

RESEARCH ARTICLE

AN AYURVEDIC METHODOLOGY FOR MANAGING DIABETIC DYSLIPIDEMIA - A CASE REPORT

Dr. Avinash Kumar Srivastava¹, Dr. Paridhi Painuly², Dr. Vandana² and Dr. Mudita Negi²

- 1. Assistant Professor, Department of Kayachikitsa, Patanjali Bhartiya Ayurvigyan Evum Anusandhan Sansthan, Haridwar.
- 2. Post Graduate Scholar, Department of Kayachikitsa, Patanjali Bhartiya Ayurvigyan Evum Anusandhan Sansthan, Haridwar.

Manuscript Info

Manuscript History Received: 28 January 2024 Final Accepted: 29 February 2024 Published: March 2024

Key words:-Diabetic Dyslipidemia, Medovahasrotas/Medovaha Srotodushti, Insulin Resistance

Abstract

ADSIFUCI

Diabetic dyslipidemia is characterized by elevated plasma triglyceride levels, decreased HDL cholesterol levels, and an increase in small dense LDL-cholesterol particles. These lipid alterations in diabetes are linked to heightened free fatty acid flux due to insulin resistance. With the availability of various lipid-lowering medications and supplements, patients now have more options to reach target lipid levels. Lipidlowering therapies in modern medicine, such as statins and fibrates, are generally well-tolerated with minimal side effects. However, these treatments often necessitate lifelong usage, which can impose significant financial strain, particularly in developing countries like India.In Ayurveda, dyslipidemia is understood as the manifestation of an imbalance in the Medovahasrotas.Dyslipidemia manifests as the consequent output of Medovahasrotodushti. A 31-year-old male patient presented with complaints of pain in calf muscles and weight gain. Upon investigation, his total cholesterol level was found to be elevated at 211 mg/dl, and triglycerides were elevated to 683.80 mg/dl. Giloykwath along with arjunkwath, Madhunashinivati extra power, Tablet lipidom, and Tablet Madhugrit were administered for the shaman therapy. Upon completion of the treatment, significant improvements were observed in the patient's complaints. Additionally, a significant improvement was noted in the Lipid Profile.

Copy Right, IJAR, 2024,. All rights reserved.

Introduction:-

The progression of technology, busy lifestyles, sedentary habits, and dietary changes have heightened individuals' susceptibility to various lifestyle disorders, with Diabetic Dyslipidemia emerging as a prominent example. Approximately 30-60% of individuals diagnosed with type 2 diabetes mellitus (T2DM) are estimated to experience dyslipidemia[1]. This prevalent metabolic abnormality, often associated with diabetes, is characterized by quantitative and qualitative changes in lipids and lipoproteins. One typical manifestation, termed diabetic dyslipidemia, involves elevated triglyceride levels, decreased concentrations of high-density lipoprotein (HDL)-cholesterol, and a shift towards small, dense low-density lipoprotein (LDL)[2].

.....

In Ayurveda, diabetic dyslipidemia can be correlated with medovahasrotodushti. Medas, one of the saptadhatu, is the fourth dhatu formed from the essence of āhāra rasa and has a maternal origin. Its principle function is the

Corresponding Author:- Dr. Paridhi Painuly

Address:- Post Graduate Scholar, Department of Kayachikitsa, Patanjali Bhartiya Ayurvigyan Evum Anusandhan Sansthan, Haridwar.

impartation of snehabhāva (unctuousness). Rasa, when solidified, converts to mamsa, which, when acted upon by mamsadhatvagni—dominated by agni, ap, and snigdha—transforms into medas. Consequently, medas is inferred as 'lipids,' and MedaDhatu as adipose tissue [3].

Medas' function is also stated as bringing about corpulence and strength due to its guru - snigdha nature. Medodushtilakshana, as outlined in Ayurvedic classics, include symptoms such as Snigdhāngata, udarapārsvavridhi, kāsa, shwas, and dourgandyam. Specific causes contributing to the vitiation of medovahasrotas include lack of exercise, daytime sleeping, consumption of fatty foods, and excessive alcohol intake. These factors have a direct effect on Kapha Pitta vitiation, which, in turn, contributes to the manifestation of Santarpanottavyadhi[4].

Bahu and abadhameda are explained as dushyavisesha in pramehanidāna, where aggravated Kaphadosha first mixes with meda, which is in surplus, non-compact form, and similar in properties to kapha. In the context of the nidāna of Madhumeha, aggravated meda is said to obstruct the path of vata, leading ojas to vastipradesha[5].

The liver plays a pivotal role in lipid metabolism, aiding in the synthesis of VLDL, HDL, TG, cholesterol, and in the synthesis and oxidation of fatty acids. Hormones of the anterior pituitary, such as GH and ACTH, promote the mobilization of fat depots, increasing lipolysis and fatty acid metabolism. Insulin facilitates the formation of fat from glucose, its deposition in adipose tissue, and prevents its breakdown. Thyroid hormones influence all major metabolic pathways by increasing basal energy expenditure through lipid, protein, and carbohydrate metabolism, affecting the synthesis, mobilization, and degradation of lipids. The suprarenals also aid in lipid metabolism via hormones of the cortex and medulla[6].

Alterations in lipid metabolism clinically present as dyslipidemia, a significant risk factor for developing atherosclerosis and heart disease. Symptoms of altered lipid metabolism manifest in conditions such as obesity, Type 1 and 2 diabetes, hypothyroidism, Cushing's syndrome, certain types of renal failure, and certain cancers. Dietary factors such as intake of fats, especially saturated fats, which account for almost 40% of total calories, and cholesterol-rich foods, as well as habitual alcohol consumption, are implicated in altered lipid metabolism. Epinephrine, with its potent lipolytic action, plays a crucial role, and its impairment is implicated in the pathogenesis of obesity. The renin-angiotensin mechanism can lead to hypertension and insulin resistance if activated in adipose tissue. Intramyocellular lipids (IMCL) are valuable energy stores, but in the absence of exercise, along with overconsumption of fat, they are positively correlated with obesity and have detrimental effects on muscular insulin sensitivity. Metabolic syndrome, defined as a conglomerate of conditions like hypertension, hyperglycemia, dyslipidemia, and increased fat around the waist occurring together, increases the risk of heart disease, stroke, and fatty kidneys demonstrate obesity's contributory role. Centuries ago, Ayurvedic classics precisely explained this morbidity of Medovahasrotas, expressed as Pramehapoorvaroopa and sthoulyalakshana, with its complications in chronic long-standing cases[7].

Material and Method

A 31-year-old male patient residing in Dehradun sought treatment at PatanjaliAyurvedic Hospital, Haridwar, in the outpatient department of Kayachikitsa in October 2023. He had previously been diagnosed with diabetes and dyslipidemia and presented with complaints of calf muscle pain persisting for three months, accompanied by weight gain and fatigue over the past year. Additionally, he reported experiencing acidity and indigestion for the past month. Laboratory tests revealed elevated total cholesterol and triglyceride levels, along with high random blood glucose levels. The patient also had a history of alcohol consumption spanning ten years.

			8	
	s.no.	Drug prescribed	Dose	anupana
Ī	1.	Arjun kwath + giloykwath	100 ml x bd before meal	-
ſ	2.	Tab. Madhunashinivati extra power	2 tab x bd before meal	Lukewarm water
		Tab. lipidom		
	3.	Tab. Madhugrit	2 tab x bd after meal	Lukewarm water

He was prescribed the following oral medications for a duration of one month: Arjun Kwath and GiloyKwath, MadhunashiniVati Extra Power, Lipidom tablets, and Madhugrit tablets.

Arjun kwath-

Terminalia arjuna (Roxb.) Wight and Arn., commonly referred to as 'Arjuna', is a medicinal plant indigenous to India with a rich history of therapeutic applications. Recognized as a cardiotonic, Arjuna has been traditionally utilized in the management of heart failure, ischemic conditions, cardiomyopathy, atherosclerosis, and myocardial necrosis. Additionally, it has been employed for addressing various human ailments such as blood disorders, anemia, venereal and viral diseases. Beyond cardiovascular health, Arjuna finds utility in treating fractures, ulcers, hepatic conditions, and exhibits a wide array of pharmacological properties including hypocholesterolemic, antibacterial, antimicrobial, antitumoral, antioxidant, antiallergic, antifeedant, antifertility, and anti-HIV activities.[8]

Giloykwath-

Sharma et al. reported significant hepatoprotective effects of Tinosporacordifolia water extract (TCE) against hepatic and gastrointestinal toxicity. In alcoholic samples, there was a notable increase in gamma-glutamyltransferase, aspartate transaminase, alanine transaminase, triglyceride, cholesterol, HDL, and LDL levels (P < 0.05), which were subsequently downregulated following TCE intervention, leading to normalized liver function. Additionally, in one study, T. cordifolia demonstrated hepatoprotective properties by markedly improving clinical and hemato-biochemical markers of CCl4-induced hepatopathy in goats. T. cordifolia extract also shielded the livers of CCl4-toxic mice, with a significant decrease observed in serum levels of SGOT, SGPT, ALP, and bilirubin post-intoxication. The herb is attributed with numerous pharmacological properties, including immunomodulation, anti-diabetic, antifungal, and hepatoprotective effects." [9]

Madhunashinivati extra power -

Madhunashinivati is made up of several medicinal herbs

Turmeric (Curcuma longa) -

The active compound in turmeric, curcumin, has garnered attention as a promising treatment for diabetes and its complications, mainly due to its safety profile and cost-effectiveness. Research indicates that curcumin acts as a potent agent in reducing glycemia and dyslipidemia in rodent models of diabetes.[10]

Kutki (**Picrorhizakurroa**) - Referred to as 'Kutki' in classical Ayurvedic texts, Picrorhizakurroa has long been utilized as a remedy for diabetes. Previous preliminary studies have corroborated its antidiabetic effects in rats, showing a significant reduction in elevated fasting blood glucose levels and effective control over dyslipidemia.[11]

Chirayata (Swertiachirayita) -

Among various herbal plants, Swertiachirayita stands out for its widespread recognition, particularly for its antihyperglycemic properties. It is acknowledged to possess a myriad of therapeutic benefits, encompassing antidiabetic, anti-inflammatory, hypoglycemic, hepatoprotective, antibacterial, wound-healing, antipyretic, antihelminthic, antioxidant, and antitussive effects.[12]

Gudmar(Gymnemasylvestre) -The administration of leaf extracts to hyperlipidemic rats for two weeks has been observed to lead to a reduction in elevated serum triglyceride (TG), total cholesterol (TC), very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterol in a dose-dependent manner. The initial scientific validation of G. sylvestre use in human diabetics' dates back almost a century, demonstrating that the leaves of G. sylvestre reduce urinary glucose levels in diabetic individuals.[13]

Hence, the additional herbs found in MadhunashiniVati, such as jamun, karela, gokhru, methi, harad, amla, and giloy, possess both antidiabetic properties and hepatoprotective qualities.

Lipidom -

Lipidom contains a potent combination of Gallic acid, Protocatechuic acid, Corilagin, Ellagic acid, Cinnamic acid, Guggulsterone E, and Guggulsterone Z. These phytometabolites are recognized for their remarkable antioxidant, anti-inflammatory, and lipid-lowering attributes. [14]

Madhugrit -

The efficacy of Madhugrit in addressing hyperglycemia and its associated complications is attributed to its rich repertoire of anti-diabetic, anti-inflammatory, antioxidant, wound-healing, and lipid-lowering phytoconstituents.

This study advocates for the translational application of Madhugrit as a potent medicine for diabetes and its comorbidities.[15]

Before treatment

Lipid profile and Blood glucose -

Date	Total cholesterol	Triglycerides	HDL	Non- HDL	Glucose fasting plasma	Hba1c
7/9/23	211.00 mg/dl	683.80 mg/dl	30.70 mg/dl	180 mg/dl	269.60 mg/dl	10.1%

an Furnerey

Regid Office: Dirt actionalitierte, faanke, sestier te Palme, New Delle Franke. Weder was in particular com CON 1248-00011975/1204-188

Name Lab No. Ref By Collected A/c Status Collected at	SELF 7/9/2023 8:49:00AM P MUZAFFAR NAGAR CC3 MUZAFFARNAGAR CC3, GALI NO.1, NEAR DR. JITENDRA SINGH RUHELA, SADAR BAZAR, MUZAFFARNAGAR 251001	Age Gender Reported Report Status Processed at	 31 Years Male 7/9/2023 6:06:12PM Final LPL-MEERUT LAB 1st Floor, Hall No. 101, 1st Floor of Shree Ram Commercial Complex Shraddhapuri, Phase 2, NH-58, Meerut, UP - 250001
--	--	--	--

Test Report

Test Name	Results	Units	Bio. Ref. Interval
LIPID SCREEN, SERUM			
Cholesterol, Total	211.00	mg/dL	<200.00
(CHO-POD)	683.80	mg/dL	<150.00
Triglycerides (GPO-POD)		1993 * 2500 -	
Advised : - Follow up and clinical correlation	n. Urgent recheck with a fresh sample	in case not correlating	
clinically.			
Result Rechecked, Please Correlate Clinically.			

	30.70	mg/dL	>40.00
HDL Cholesterol (CHO-POD)		mg/d∟	<130
Non-HDL Cholesterol (Calculated)	180		

1	Regul Difference Web	1. a faste pharmal, Barriel V., and Henriel Albert - Ann 1986, I January V. (1997), and	(4.94 (1996) 1997) (197) (1986)
ne : NO. : collected : 6/9/2023 9:35:00AM vollected : P collected at : MUZAFFAR NAGAR CC3 MUZAFFARNAGAR CC3, GALI NO 1, NEAR DR. JITENDRA SINGH RUHELA, SADAR INAZAR, MUZAFFARNAGAR 251001	Age Gender Reported Report Statum Processed at	31 Years Male Wolv2023 8:35:06PA Final LPL.MEERUT LAB tel Floor, Hall No. 10 Ram Commercial Cor Straddhapun, Phase UP - 250001	t, 1et Floor of Shree splex,
	Test Report		17110
Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HPLC, NGSP certified)			
HDA1c	10.1	76	4 00 - 5 60
Estimated average glucose (eAG)	243	mg/dL	

br Lal PathLabs Regul Office: On Existence on the Hark 1 -sector is detailed by the two transmission $W(\theta)$ -sector of the transmission $D(\theta)$. Detailed of the process sets : Mr. ALOK BARTHWAL : 440786199 ; 31 Years Age , NO : SELF : Male Gender or By collected : 6/9/2023 9:35:00AM Reported 6/9/2023 8:35:06PM 5 Aic Status ; P Report Status - 20 Final collected at : MUZAFFAR NAGAR CC3 : LPL-MEERUT LAB Processed at MUZAFFARNAGAR CC3, GALI NO.1, NEAR DR. 1st Floor, Hall No. 101, 1st Floor of Shree JITENDRA SINGH RUHELA, SADAR BAZAR, Ram Commercial Complex, Shraddhapuri, Phase 2, NH-58, Meerut, UP - 250001 MUZAFFARNAGAR 251001 Test Report

Test Namo	Results	Units	Bio, Ref. Interval
GLUCOSE, FASTING (F), PLASMA	269.60	mg/dL	70.00 - 100.00
(Hexokinase)			

After treatment

Lipid profile and blood glucose -

Date	Total cholesterol	Triglycerides	HDL	VLDL	Glucose fasting plasma	Hba1c
24/11/23	182 mg/dl	208 mg/dl	44.5 mg/dl	41.60 mg/dl	103 mg/dl	5.81%

and for they conducted a woman of a set	ology Lab) "Reliable Testing	STICS	Dr. Priyanka Gu MBB:
Patient Name : Age / Gender : 31 years / Male	Seen to Y	Collection Tin	ne : Nov 24, 2023, 12:30 p.m.
Patient ID : Source : cc- gumaniwala		Reporting Times Sample ID :	te : Nov 24, 2023, 04:40 p.m.
Test Description	Value(s)	Reference Range	Unit
BLOOD SUGAR FASTING			1 Street man
Result	103	8d-<1m: 50-10 1m-11m: 50-1 1y-18y: 60-1	00 mg/dl. mg/dl 30 mg/dL 00 mg/dL 100 mg/dL 100 mg/dL
HBA1c (GLYCOSYLATED Hb)		Market and the second	and the second of
TYPE OF SPECIMEN :	WHOLE BLO		
Method		methylammonium bromide	
Result	5.81	Normal (nondiabetic): Prediabetes: Diagnosis of Diabetes	5.9 - 6.4%
Interpretation Hemoglobin/Allc (glycated hemoglobin Inestan, roughly 120 days in normal	a) reflects the average blo individuals. It provides d	od glucose concentration of	ver the course of the RBC ry, information to a single glucor but of therapy is to attain a value
Hemoniobin A1c (glycated hemoglobin licespan, roughly 120 days in normal concentration. Hemochelin A1c shoul of less than 7.0% (while minimizing h generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1c(%) Mean Plasma G 6	individuals in provident of the production of the product of the prod	in diabetic patients. The g	poil of therapy is to attain a who ing every 1 to 4 months is major change in therapy, it may
Hemoniobin A1c (glycated hemoglobin Inespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 IbbA1cf%) Mean Plasma G 6 7	individual, it is debenomicered regularly popylycerime episodes)) F istuations, such as gest week intervals; iucose (mg/dL) 126	in diabetic patients. The g	poil of therapy is to attain a who ing every 1 to 4 months is major change in therapy, it may
Hemoniobin A1c (glycated hemoglobin Inespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of Ir us than 7.0% (while miniming h generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 5	individual, it is the second regularity popplycermic episodesis F I situations, such as gest week intervals, lucose (mg/dL) 126 154 183 212	in diabetic patients. The g	poil of therapy is to attain a who ing every 1 to 4 months is major change in therapy, it may
Hemoniobin A1c (glycated hemoglobin Inespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 IbbA1cf%) Mean Plasma G 6 7	individual, it is a second regularity popply of mic episodes of a situations, such as gest week intervals. Jucose [mg/dL] 126 154 183 212 240	in diabetic patients. The g	poil of therapy is to attain a who ing every 1 to 4 months is major change in therapy, it may
Hemoniobin A1c (glycated hemoglobin litespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing for generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1c(%) Mean Plasma G 6 7 8 9	individual, it is the second regularity popplycermic episodesis F I situations, such as gest week intervals, lucose (mg/dL) 126 154 183 212	in diabetic patients. The g	poil of therapy is to attain a who ing every 1 to 4 months is major change in therapy, it may
Hemoniobin A1c (glycated hemoglobin Inespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of Ir vs than 7.0% (while minimizing b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1c(%) Mean Plasma G 6 7 8 9 10 11 12	individual, it is a second is bein control in regularity property control in regularity provide intervals, success (mg/dL) 126 154 183 212 240 269 298	In diabetic patients. The s or Latine characteristic use dest attional diabetes, or after a Stiring), Accurre	and of theirapy is to attain a mini ing every it to 4 months is major change in therapy, it may inter Diagnostis
Hemoniobin A1c (glycated hemoglobin litespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing h generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1c(%) Mean Plasma G 6 7 8 9 10 11	individual, it is a second is bein control in regularity property control in regularity provide intervals, success (mg/dL) 126 154 183 212 240 269 298	In diabetic patients. The s or Latine characteristic use dest attional diabetes, or after a Stiring), Accurre	and of theirapy is to attain a mile ing every it to 4 months is major change in therapy, it may the Diagnosis
Hemoniobin A1c (glycated hemoglobin Inespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of Ir is than 7.0% (while minimizing b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1c(%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE	individual, it is a second regularity popplycermic episodesis P isituations, such as gest week intervals, lucose (mg/dL) 126 154 153 212 240 269 298 SERUM SPECTROPH	in diabetic patients. The g	net of therapy it to attain a mile ing every it to 4 months is major change in therapy, it may the Diagnosis
Hemoniobin A1c (glycated hemoglobin Inceptin, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while miniming b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE TYPE OF SPECIMEN :	individual, it is a second is bein control in regularity property control in regularity provide intervals, success (mg/dL) 126 154 183 212 240 269 298	or disperie patients The s or Justice Characteries ational diabetes, or after a String, Accurre OTOMETRY, CALCULATION	nel of therapy it to attain a min ing every it to 4 months is major change in therapy, it may the Diagnosts
Hemoniobin A1c (glycated hemoglobin licespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing h generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE TYPE OF SPECIMEN : METHOD Total Cholesterol Triglyceride	individuals. It is a set of the s	or disperie patients The s or Justice Characteries ational diabetes, or after a String, Accurre or other and the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the string of the s	net of therapy it to attain a mile ing every it to 4 months is major change in therapy, it may the Diagnosis
Hemoniobin A1c (glycated hemoglobin Intespin, roughly 120 days in normal concentration. Hemoglobin A1c shoul of Ir vs than 7.0% (while miniming b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE TYPE OF SPECIMEN : METHOD Total Cholesterol	Individual, it is the second s	or disperse patients the st or further characterist ational diabetes, or after a String, Accurre OTOMETRY, CALCULATION < 200 < 150	ng/dl mg/dl mg/dl mg/dl
Hemoniobin A1c (glycated hemoglobin licespan, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while minimizing h generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE TYPE OF SPECIMEN : METHOD Total Cholesterol Triglyceride	Individual, it is a set of the se	or disperse patients the s or output children used est ational diabetes, or after a string, Accurre otometray, CALCULATION < 200 < 150 > 40	ng/dl mg/dl mg/dl mg/dl
Hemoniobin A1c (glycated hemoglobin Incernation, roughly 120 days in normal concentration. Hemoglobin A1c shoul of less than 7.0% (while miniming b generally sufficient. In certain clinical be useful to measure HbA1c in 2 to 4 HbA1cf%) Mean Plasma G 6 7 8 9 10 11 12 LIPID PROFILE TYPE OF SPECIMEN : METHOD Total Cholesterol Triglyceride HDL Cholesterol	Individual, it is a set of the se	or disperse patients the s or output children used est ational diabetes, or after a string, Accurre otometray, CALCULATION < 200 < 150 > 40	ng/dl mg/dl mg/dl mg/dl

Discussion

Dyslipidemia stands out as a significant risk factor for cardiovascular disease in individuals with diabetes mellitus. Timely identification and management of dyslipidemia in type-2 diabetes can effectively mitigate the risk of atherogenic cardiovascular disorders. Diabetic dyslipidemia encompasses a triad of elevated triglycerides, diminished HDL cholesterol, and an abundance of small, dense LDL particles. These lipid irregularities are widespread in diabetes mellitus due to the impact of insulin resistance or deficiency on crucial enzymes and pathways in lipid metabolism.

In Ayurveda, diabetic dyslipidemia finds correlation with 'medovahasrotodushti,' wherein the vitiation of medovahasrotas influences the imbalance of Kapha and Pitta doshas, thereby contributing to the manifestation of 'Santarpanottavyadhi.' Consequently, Ayurvedic treatment aims to restore the equilibrium of Kapha and Pitta doshas, enhance metabolism, and stimulate hepatic functions. In this case study, we administered medications that pacify Kapha and Pitta doshas while also possessing anti-diabetic, anti-inflammatory, and hepatoprotective properties."

Result

The patient demonstrated positive progress within four months, with noticeable improvement in his complaints of pain and fatigue. Moreover, his lipid profile and blood glucose levels exhibited significant and marked changes. The patient expressed satisfaction, and no adverse drug reactions were observed throughout the treatment.

Refrences

- 1. Feingold KR. Dyslipidemia in Patients with Diabetes. [Updated 2023 Dec 4]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
- 2. https://www.sciencedirect.com/science/article/abs/pii/S0026049514002583#preview-section-cited-by
- 3. https://archive.org/details/ShabdaKalpadrumaComplete/page/n2095/mode/2 up?q=medas. Wed Sept 09 2020 19:25Hrs.
- 4. Dr.SubhashRanade, Dr.R.R.Deshpande and Dr.SwatiChoubhe, A textbook of SharirKriyaVijnana , Part 2, Chaukhambha Sanskrit Pratisthan. p.58.
- 5. Pt. Brahma Shankara Mishra, VidyotiniTeeka- Bhavaprakash, vol2, Choukamba Sanskrit Bhavan (2015).
- 6. Vera B Schrauwen-Hinderlinget.al,Intramyocellular Lipid Content in Human Skeletal Muscle, Obesity (Silver Spring) 2006.
- https://www.mayoclinic.org/diseases-conditions/metabolicsyndrome/symptoms-causes/syc-20351916. Mon Aug 31 2020 01:50Hrs.
- Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight &Arn.: A review. J Tradit Complement Med. 2016 Mar 20;7(1):65-78. doi: 10.1016/j.jtcme.2016.02.003. PMID: 28053890; PMCID: PMC5198828.
- 9. https://sifisheriessciences.com/journal/index.php/journal/article/view/1934/1990
- Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013;2013:636053. doi: 10.1155/2013/636053. Epub 2013 Nov 24. PMID: 24348712; PMCID: PMC3857752.
- 11. Husain, Gulam& Rai, Richa& Rai, Geeta& Singh, Harikesh& Thakur, Dr.Ajit& Kumar, Vikas. (2014). Potential mechanism of anti-diabetic activity of Picrorhizakurroa. TANG. 4. 27. 10.5667/tang.2014.0013.
- Dey P, Singh J, Suluvoy JK, Dilip KJ, Nayak J. Utilization of Swertiachirayita Plant Extracts for Management of Diabetes and Associated Disorders: Present Status, Future Prospects and Limitations. Nat Prod Bioprospect. 2020 Dec;10(6):431-443. doi: 10.1007/s13659-020-00277-7. Epub 2020 Oct 28. PMID: 33118125; PMCID: PMC7648839.
- 13. Saneja, Ankit & Sharma, Chetan&Aneja, K. &Pahwa, Rakesh. (2009). GymnemaSylvestre (Gurmar): A Review. 2.
- 14. Acharya Balkrishna, VivekGohel, Nishit Pathak, Rani Singh, MeenuTomer, MaliniRawat, Rishabh Dev, Anurag Varshney, Anti-oxidant response of lipidom modulates lipid metabolism in Caenorhabditiselegans and in OxLDL-induced human macrophages by tuning inflammatory mediators, Biomedicine&Pharmacotherapy, Volume 160, 2023, 114309, ISSN 0753-3322.
- Balkrishna A, Gohel V, Pathak N, Tomer M, Rawat M, Dev R, Varshney A. Anti-hyperglycemic contours of Madhugrit are robustly translated in the Caenorhabditiselegans model of lipid accumulation by regulating oxidative stress and inflammatory response. Front Endocrinol (Lausanne). 2022 Dec 5;13:1064532. doi: 10.3389/fendo.2022.1064532. PMID: 36545334; PMCID: PMC9762483.